By a GenomeWeb staff reporter
This story originally ran on Dec. 13.
Biodesix last week presented results from a retrospective analysis of breast cancer patients using its serum proteomic Veristrat diagnostic.
By Molika Ashford
Abbott said this week that it has expanded an existing immunotherapy companion diagnostic development agreement with GlaxoSmithKline to include a new target antigen.
Originally published Nov. 29.
Abbott and GlaxoSmithKline this week formally extended an existing drug/diagnostic codevelopment partnership in the cancer immunotherapy space, setting their sights on a new marker: the PRAME antigen.
A study published this month in the Journal of Thoracic Oncology supports the usefulness of Biodesix's VeriStrat lung cancer diagnostic in monitori
By Ben ButkusThis story has been updated from a version posted Oct. 25 to include comments from a GlaxoSmithKline spokesperson.
In PLOS this week: transcriptomic and genomic analysis of prostate cancer by ancestry, genes linked to liver function in Korean cohort, and more.
British Columbia is incorporating genomics into its tracking of the ongoing COVID-19 outbreak, Business in Vancouver reports.
An analysis by the Personalized Medicine Coalition finds that about a quarter of new drugs approved in 2019 by the US Food and Drug Administration were personalized medicines.
The governor of New York has proposed a five-year plan to study the genomes of people with or who are at high risk of developing Alzheimer's disease.